Biogen Idec Initiates Pivotal Lumiliximab CLL Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Company tells “The Pink Sheet” DAILY it hopes for a 2009 launch of the chronic lymphocytic leukemia therapy.
You may also be interested in...
Genta Will Appeal FDA “Not Approvable” Action On Genasense
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Rituxan Adds Third NHL Indication In 2006
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.